biotech
biotech Articles
Jounce Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
FibroGen could be a very important stock in its sector in 2017, with its data from multiple studies coming out early in the year.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
Published:
Last Updated:
Shares of Cempra were halved on Thursday after the company received a Complete Response Letter from the U.S. Food and Drug Administration (FDA).
Published:
Last Updated:
Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA) approval. The company announced that it has confirmed the regulatory pathway...
Published:
Last Updated:
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Published:
Last Updated:
Seattle Genetics shares were down double-digits after the company announced that the FDA has placed holds on several early-stage clinical trials of its leukemia drug candidate.
Published:
Last Updated:
Visterra has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
In a new research report, the biotech team at RBC reveal their top picks for 2017, and while hardly pounding the table, they are cautiously optimistic.
Published:
Last Updated:
Akebia Therapeutics shares saw a handy gain on Tuesday after the company reported a new collaboration with Otsuka Pharmaceutical.
Published:
Last Updated:
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares hit a new 52-week high after the company reported a key U.S. Food and Drug Administration (FDA) approval. Essentially, the FDA approved...
Published:
Last Updated:
TiGenix intends to offer more than 2 million American depositary shares in its initial public offering and to list on the Nasdaq.
Published:
Last Updated:
Achaogen has priced its more than 6 million share offering at $13.50 per share in a secondary offering valued up to roughly $101 million.
Published:
Last Updated:
Achaogen, Inc. (NASDAQ: AKAO) saw its shares continue to rise late on Tuesday after the company reported that it would conduct a secondary offering. The company said that it would be offering up to...
Published:
Last Updated:
Proteon Therapeutics saw its shares absolutely crater on Tuesday after the company reported top-line results from its late-stage chronic kidney disease trial.
Published:
Last Updated: